AstraZeneca's flu vaccine sales may have just gotten a boost, courtesy of federal regulators. Wednesday, they recommended that healthy children 2 to 8 years old receive the company's nasal spray flu vaccine FluMist in lieu of flu shots when available.
AstraZeneca's top investigators took their best case for an accelerated approval of the failed cancer drug olaparib to the FDA's panel of outside experts on Wednesday, and they lost.
Molecular diagnostics company Cepheid is partnering with pharma giants AstraZeneca, Cubist Pharmaceuticals and GlaxoSmithKline to develop a rapid diagnostic test that can target multi-drug resistant pathogens to help doctors appropriately prescribe antibiotics.
AstraZeneca's reconstructed case for the cancer drug olaparib is built on the fundamental premise that the new management team at the pharma giant is a whole lot smarter than the old crew. After a retrospective analysis found a subgroup response in the data for ovarian cancer, CEO Pascal Soriot not only ordered the team to renew its pursuit of an approval, he later assigned a $2 billion peak sales value to the program.
Critics of siloed Big Pharma R&D often point to the untapped potential of leading firms' compound libraries as evidence of the need for greater openness. Giving a wider pool of researchers with IT and high-throughput screening skills, access to the libraries could uncover new drugs, an idea AstraZeneca is putting to the test by sharing compounds with certain researchers.
Manufacturing snafus have delayed copycat versions of Novartis' blood pressure drug Diovan, AstraZeneca's stomach-acid remedy Nexium and Roche's antiviral drug Valcyte.
With Pfizer's unwanted buyout bid in the past--at least for now--AstraZeneca needs to cheer up some of its shareholders. After all, some top investors in the U.K.-based drugmaker wanted to cash in on the proposed takeover. So, once again, CEO Pascal Soriot is making his case for AstraZeneca's bright future.
When Sanofi bought Genzyme, the deal was clinched on a contingent value right (CVR) based on the potential multiple sclerosis treatment Lemtrada. Could Pfizer do the same thing to win over AstraZeneca?
Convening in San Francisco for the annual conference of the American Diabetes Association this weekend, drugmakers angled for the spotlight in a field made up mostly of similar treatments with small differentiations that could spell the difference between blockbuster sales and also-ran status.
With AstraZeneca's CFO telling investors that Pfizer's colossal takeover bid failed purely because it was too cheap, creative dealmakers are looking at new ways to get the two parties shaking hands.